Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Nathan den Broeder¹, Michelle Mulder¹, Mark Wenink¹, Alfons den Broeder¹, Lise Verhoef², Frank van den Hoogen¹ and C.A.J Michielsens¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…
Abstract Number: 0642 • ACR Convergence 2020
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Marta González Fernández¹, Orlando Pompei fernández², Joaquín María Belzunegui Otano³, Paula García Escudero¹, Claudia Stoye², Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Xenofon Baraliakos¹, Annette Szumski², Kenneth Kwok³ and Bonnie Vlahos⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Syneos Health, Princeton, ³Pfizer, New York, NY, ⁴Pfizer, Collegeville, PA
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…
Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Ching-Huang Ho¹, Andrea Silva¹ and I-Cheng Ho², ¹Brigham and Women's Hospital, Boston, MA, ²Birgham and Women's Hospital, Boston, MA
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
Abstract Number: 0710 • ACR Convergence 2020
Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?
Alina Lucica Boteanu¹, Andrea Briones-Figueroa², Laura Calvo-Sanz², África Andreu Suárez² and Antía García-Fernández², ¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: Data about when is the best moment to start BT in Juvenile Idiopathic Arthritis (JIA) patients and the impact of this prompt initiation are…
Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 1406 • ACR Convergence 2020
LAG-3+ T Cells Are Diminished in Active Psoriatic Arthritis Patients and Their Restoration in Vitro Is Mediated by TNF Inhibitors
Smadar Gertel¹, Ari Polachek², Victoria Furer³, David Levartovsky³ and Ori Elkayam⁴, ¹Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ³Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. Aberrant T cell regulation has been implicated in the process of inflammation in…
Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
Abstract Number: 1045 • ACR Convergence 2020
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
Inigo Gonzalez-Mazon¹, Alba Herrero Morant², Lara Sanchez-Bilbao², David Martinez-Lopez³, Vanesa Calvo-Río⁴, Carmen Alvarez-Reguera², Santos Castañeda⁵, Esther Francisca Vicente-Rabaneda⁶, Rosalia Demetrio-Pablo², Ana Urruticoechea-Arana⁷, J. L. García-Serrano⁸, J. L. Callejas-Rubio⁸, Norberto Ortego⁸, José Luis Martín-Varillas⁹, Olga Maiz Alonso¹⁰, Ana Blanco¹¹, Francisco Javier Narváez¹², Susana Romero-Yuste¹³, Iñigo Rúa-Figueroa¹⁴, Paula Estrada¹⁵, Julio Sanchez¹⁶, Miguel Ángel González-Gay¹⁷ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁴H.U. Marques de Valdecilla, Santander, Spain, ⁵Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ⁷HOSPITAL CAN MISSES EIVISSA, Ibiza, Spain, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Spain, ¹²Hospital Bellvitge, BARCELONA, Spain, ¹³H Pontevedra, Coruna, Spain, ¹⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital 12 Octubre, Madrid, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating…
Abstract Number: 1544 • ACR Convergence 2020
Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Mara Leach¹, David Ralph¹, Beth Potter¹, Bonnie Abbruzzese¹, Rachael Hershey¹, Jessica Fitzpatrick¹, Katherine Repp¹, Haya Shakhtra¹, Madison Palmer¹, Nicole Korczak¹, Audrey Villarosa¹, Michael Blue¹, Martin Jacobs², Yelliann Ruis³, Debbie Foley⁴, Alan Kivitz⁵ and Michael Rosol¹, ¹Navidea Biopharmaceuticals, Dublin, ²Kettering Medical Center, Kettering, ³Innovation Medical Research Center, Palmetto Bay, ⁴Premier Rheumatology of Oklahoma, Tulsa, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA
Background/Purpose: Rheumatoid Arthritis (RA) is a serious and potentially debilitating disease, but low disease activity and even clinical remission can be obtained if an effective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].